by Michael Boyd | Jul 25, 2023 | Publications
Since the vast majority of their assigned disease burden costs are driven by the assumption that “loss of IQ” and “increased prevalence of intellectual disability” are caused by exposures to organophosphate pesticides (OPPs) and brominated flame retardants (PBDEs), we...
by Michael Boyd | Jul 25, 2023 | Publications
Published recommendations are used to evaluate data validity for testing each hypothesis and quantitative weightings are proposed to reflect two data parameters. Relevance weightings should be derived for each endpoint to reflect the degree to which it probes each...
by Michael Boyd | Jul 25, 2023 | Publications
Rank 1 was assigned to in vivo endpoints that characterize the fundamental physiological actions for androgen, estrogen, and thyroid activities. Rank 1 endpoints are specific and sensitive for the hypothesis, interpretable without ancillary data, and rarely confounded...
by Michael Boyd | Jul 25, 2023 | Publications
Resolving whether MTBE exhibits endocrine activity is important given regulatory and public interest in endocrine disrupting substances and their potential for causing adverse effects in humans or wildlife. A weight-of-evidence (WoE) analysis was conducted, focusing...
by Michael Boyd | Jul 25, 2023 | Publications
A group promoting the importance of non-monotonic dose responses for endocrine disruptors contend that scoring systems giving primacy to GLP are biased against non-GLP studies from the literature and are merely record-keeping exercises to prevent fraudulent reporting...
Recent Comments